Kamada Ltd. has reported preliminary data from its ongoing extension study of a Phase I/II clinical trial with its lead product Glassia to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D). In T1D endogenous insulin production is compromised, and with time progressive deterioration of beta-cell reserve occurs due to the continuous autoimmune attack. New interim data from the ongoing extension study showed that at ~20 months from T1D diagnosis and ~10 months following the ...